Emotional awareness therapy shows promise for migraine sufferers
NCT ID NCT05837650
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested a new behavioral treatment called Emotional Awareness and Expression Therapy (EAET) for people with migraines. Thirty adults with frequent migraines were randomly assigned to either EAET or a control group. The therapy involved 8 weekly online sessions where participants learned to identify and express suppressed emotions. The goal was to see if EAET could reduce the number of migraine days and improve quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Emotional Awareness and Expression Therapy (EAET)
- What this could lead to
- If it works, this could offer a new drug-free way to reduce migraine attacks and improve quality of life.
- What could go wrong
- This is a very small pilot study with only 30 participants, so results may not apply to everyone. The therapy requires significant time and effort, and it may not work for all migraine types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dan Kaufmann
Salt Lake City, Utah, 84117, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted botox shot quiet the Brain's pain center for chronic migraine?
- Could a symptom registry unmask hidden migraine variants?
- Melatonin may double up against childhood migraines
- Online sleep therapy may ease migraines in teens
- Scientists aim to forecast migraine pain using wearable sensors and early symptoms
- Migraine drug AJOVY under Real-World safety spotlight